Key terms
About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MRNA news
Apr 17
2:00pm ET
Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
Apr 15
5:48am ET
Novavax (NASDAQ:NVAX) Jumps Amid Activist Investor Push
Apr 12
11:08am ET
Biotech Alert: Searches spiking for these stocks today
Apr 11
11:59am ET
Moderna (NASDAQ:MRNA) Postpones Plans of Vaccine Plant in Kenya
Apr 11
6:34am ET
Moderna pauses efforts to build vaccine plant in Kenya, FT says
Apr 09
1:32pm ET
Moderna’s (NASDAQ:MRNA) Latest Treatment Line Gives Shares New Life
Apr 09
8:10am ET
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Ocugen (OCGN) and Moderna (MRNA)
Apr 09
7:13am ET
Analysts Are Bullish on These Healthcare Stocks: Inozyme Pharma (INZY), Moderna (MRNA)
Apr 08
11:00pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Apr 08
2:43pm ET
Moderna Stock (NASDAQ:MRNA): This mRNA Tech Pioneer Has Rebound Potential
Apr 04
8:38am ET
Arbutus ‘pleased’ with claim construction ruling in patent infringement suit
Apr 03
3:05pm ET
Moderna could owe $1B-$3B in royalties, says Jefferies
Apr 03
2:02pm ET
Roivant, Arbutus higher after ruling on COVID patent order
Apr 03
1:56pm ET
Jefferies sees Roivant rallying 5%-10% on today’s COVID patent order
Apr 03
11:07am ET
Moderna announces publication of Phase 1/2 interim data on mRNA-3927
Apr 02
8:10am ET
Analysts Are Bullish on Top Healthcare Stocks: Veeva Systems (VEEV), Moderna (MRNA)
Mar 29
3:07am ET
Maintaining Sell Rating on Moderna Amid Financial Strains and Competitive Pressures
Mar 28
8:00am ET
Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Altimmune (ALT)
Mar 28
7:55am ET
Buy Rating Affirmed for Moderna Amid Strategic Partnerships and Promising Vaccine Pipeline
Mar 28
7:05am ET
Balancing Scientific Progress with Market Realities: Moderna’s Hold Rating Explained
Mar 28
7:00am ET
Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Akebia Therapeutics (AKBA) and Moderna (MRNA)
Mar 28
6:35am ET
RBC Capital Sticks to Its Buy Rating for Moderna (MRNA)
Mar 28
5:55am ET
Moderna’s Promising Vaccine Pipeline Balanced with Near-Term Caution: Hold Rating Maintained
Mar 28
5:01am ET
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Argenx Se (ARGX) and NovoCure (NVCR)
Mar 27
8:45am ET
Moderna to host investor event
Mar 27
6:39am ET
Moderna advances multiple vaccine programs to clinical trials
Mar 27
6:37am ET
Blackstone to provide up to $750M to fund Moderna’s influenza program
Mar 27
5:55am ET
Moderna to host investor event
Mar 26
5:19pm ET
Moderna to host investor event
Mar 26
10:41am ET
Moderna’s Next-Gen COVID Vaccine Triumphs in Trial
Mar 25
9:56am ET
Early notable gainers among liquid option names on March 25th
Apr 17
7:00am ET
Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
Apr 03
11:00am ET
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Mar 27
6:30am ET
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Mar 26
7:00am ET
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
MRNA Financials
Key terms
Ad Feedback
MRNA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MRNA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range